Back to Search Start Over

NMDAR antagonists for the treatment of diabetes mellitus-Current status and future directions.

Authors :
Welters, Alena
Klüppel, Carina
Mrugala, Jessica
Wörmeyer, Laura
Meissner, Thomas
Mayatepek, Ertan
Heiss, Christian
Eberhard, Daniel
Lammert, Eckhard
Source :
Diabetes, Obesity & Metabolism; Sep2017 Supplement S1, Vol. 19, p95-106, 12p
Publication Year :
2017

Abstract

Diabetes mellitus is characterized by chronically elevated blood glucose levels accelerated by a progressive decline of insulin-producing β-cells in the pancreatic islets. Although medications are available to transiently adjust blood glucose to normal levels, the effects of current drugs are limited when it comes to preservation of a critical mass of functional β-cells to sustainably maintain normoglycemia. In this review, we recapitulate recent evidence on the role of pancreatic N-methyl-D-aspartate receptors (NMDARs) in β-cell physiology, and summarize effects of morphinan-based NMDAR antagonists that are beneficial for insulin secretion, glucose tolerance and islet cell survival. We further discuss NMDAR-mediated molecular pathways relevant for neuronal cell survival, which may also be important for the preservation of β-cell function and mass. Finally, we summarize the literature for evidence on the role of NMDARs in the development of diabetic long-term complications, and highlight beneficial pharmacologic aspects of NMDAR antagonists in diabetic nephropathy, retinopathy as well as neuropathy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14628902
Volume :
19
Database :
Complementary Index
Journal :
Diabetes, Obesity & Metabolism
Publication Type :
Academic Journal
Accession number :
125027112
Full Text :
https://doi.org/10.1111/dom.13017